Having priced its shares at the top of its range, UChicago spinout Pyxis Oncology suffered a drop on the first day of trading.

The Bloomberg Beta-backed quantum chipmaker is joining forces with the publicly listed Supernova Partners Acquisition Company II.

The cancer drug developer has closed its initial public offering after underwriters exercised the greenshoe option.

The cancer drug developer has closed an initial public offering which took place alongside a $160m SoftBank-led private placement.

The Benesse and Prosus-backed online learning platform operator has filed to list on Nasdaq, about a year after closing a series F round at a $3.25bn valuation.

Canon, Kansai Electric Power, Mitsui Fudosan, NEC, NTT Docomo, So-net and T-Gaia were among the investors that scored exits as the CCTV system provider went public.

The immuno-oncology drug developer’s prospective initial public offering would mark exits for Takeda, Merck Group, Ipsen and Merck & Co.

The fashion rental service has officially filed to go public having raised over $500m from investors including Advance Publications and American Express.

The diversified therapeutics developer has filed to go public in the United States a year after Pfizer contributed to its $310m series A round.

UChicago spinout Pyxis Oncology is aiming to raise more than $153m in its initial public offering, having set a price range of $14 to $16.